Technical Analysis for VRNA - Verona Pharma plc

Grade Last Price % Change Price Change
grade D 6.42 4.73% 0.29
VRNA closed up 4.73 percent on Thursday, April 18, 2019, on 1.13 times normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical VRNA trend table...

Date Alert Name Type % Chg
MACD Bullish Centerline Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Gapped Up Strength 0.00%
MACD Bearish Centerline Cross Bearish 4.73%
Crossed Above 50 DMA Bullish 4.73%
Hammer Candlestick Bullish 4.73%
Lizard Bullish Bullish Day Trade Setup 4.73%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.73%
Narrow Range Bar Range Contraction 4.73%
Doji - Bullish? Reversal 4.73%

Older signals for VRNA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.
Medical Specialties Respiratory Therapy Asthma Cystic Fibrosis Chronic Obstructive Pulmonary Disease Respiratory Diseases Pulmonology Lactams Treatment Of Chronic Obstructive Pulmonary Disease
Is VRNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Apr 9 Verona Pharma nabs additional patent in Europe
Apr 9 Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
Apr 4 Grant of Options and RSUs and PDMR Dealings
Mar 26 Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
Mar 22 2018 Annual Report and Accounts and Notice of AGM 
Mar 21 Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
Mar 13 Verona Pharma (VRNA) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow
Mar 7 PDMR Dealing
Mar 4 Verona up 4% on positive ensifentrine data
Mar 4 Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
See more VRNA news...
Indicators
Indicator Value
52 Week High 22.35
52 Week Low 5.52
Average Volume 8,835
200-Day Moving Average 10.3885
50-Day Moving Average 6.1357
20-Day Moving Average 6.4355
10-Day Moving Average 6.3505
Average True Range 0.3044
ADX 27.17
+DI 27.9939
-DI 17.8636
Chandelier Exit (Long, 3 ATRs ) 6.0168
Chandelier Exit (Short, 3 ATRs ) 6.8132
Upper Bollinger Band 6.8547
Lower Bollinger Band 6.0163
Percent B (%b) 0.48
BandWidth 13.027737
MACD Line 0.0002
MACD Signal Line 0.0293
MACD Histogram -0.0291
Fundamentals Value
Market Cap 71.03 Million
Num Shares 11.1 Million
EPS -1.51
Price-to-Earnings (P/E) Ratio -4.25
Price-to-Sales 0.00
Price-to-Book 1.25
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.79
Resistance 3 (R3) 6.75 6.59 6.73
Resistance 2 (R2) 6.59 6.49 6.61 6.71
Resistance 1 (R1) 6.50 6.43 6.54 6.54 6.69
Pivot Point 6.34 6.34 6.36 6.36 6.34
Support 1 (S1) 6.25 6.24 6.30 6.30 6.15
Support 2 (S2) 6.09 6.18 6.11 6.13
Support 3 (S3) 6.00 6.09 6.11
Support 4 (S4) 6.05